Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Monoclonal Antibodies Market For Breast Cancer To More Than Double By 2019, But Unmet Need Still To Be Fulfilled

Monoclonal Antibodies Market for Breast Cancer to More than Double by 2019, but Unmet Need Still to be Fulfilled, according to Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

The market value for monoclonal antibodies (mAbs) in breast cancer treatment will experience a massive increase from $4.8 billion in 2012 to $10.9 billion in 2019, demonstrating a Compound Annual Growth Rate (OTCPK:CAGR) of 12.2%, according to Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth.

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth states that this double-digit increase will be driven mainly by the uptake of two recent approvals, Perjeta and Kadcyla, along with the rapid year-on-year growth in specialty pharmaceuticals in the US, which boasts the largest regional market for breast cancer treatment.

Roche is currently the dominant player within this market, with a franchise of drugs (including the blockbuster Herceptin) that target the Human Epidermal growth factor Receptor-2 (HER-2), which is overexpressed in 20-25% of breast cancer patients.

However, as there are currently no effective mAbs for patients who do not overexpress this protein, a strong unmet need remains in this area, particularly in patients with the metastatic form of the disease.

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth: "For the majority of patients diagnosed in the early stages of breast cancer, survival rates are high, ranging from 80% to almost 100%. However, stage IV breast cancer is incurable, as with all other forms of metastatic cancer, so the primary treatment goal is limited to effective tumor remission over an extended period of time.

"While chemotherapy, surgery and radiation therapy are able to improve outcomes to an extent, mAb products that are currently available in the market are far more effective and safe than chemotherapy in this regard, affording a superior standard of care in suitable patients. The development of these products to provide greater survival benefits to patients diagnosed with metastatic breast cancer is therefore an obvious goal." - Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

According to Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth, a realistic next step in terms of manufacturing novel mAb products would be to build on the benefit provided by the current range of marketed products and improve survival times further, with fewer side-effects.

"As 75% of the patient population is currently unable to benefit from mAb therapies, a new market entrant that is not specifically indicated for HER-2 positive cancers would face little competition. This therefore presents a very strong commercial opportunity for drug developers within this particular market segment," Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth concludes.

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth provides an introduction to the treatments available for breast cancer, treatment algorithms and the contexts in which monoclonal antibodies (mAbs) are clinically relevant to this type of cancer. It provides analysis of the five mAbs approved for breast cancer, including their safety, efficacy, treatment patterns and strengths and weaknesses, along with a comprehensive review of the pipeline for breast cancer therapies.